Clinical Trials Browser

Pancreatic Neoplasms, Neoplasm, Residual

NCT07517705 2026-05-13

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

50 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07572929 2026-05-07

PREeMPT

Phase 2 Not yet recruiting

450 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07514715 2026-04-13

RT4

Not yet recruiting

129 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

10 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

69 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

Phase 1/2 Not yet recruiting

31 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07483476 2026-03-19

CIRCALL

Not yet recruiting

205 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07454486 2026-03-06

TRACE-BTC

Not yet recruiting

300 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Neoplasms, Cholangiocarcinoma, Klatskin Tumor, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

330 enrolled

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

100 enrolled

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT07382505 2026-02-02

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Not yet recruiting

600 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Phase NA Not yet recruiting

276 enrolled

Recurrence, Neoplasm, Residual

NCT07112612 2026-01-12

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

Not yet recruiting

50 enrolled

Genitourinary

Prostatic Neoplasms, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

23 enrolled

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07269067 2025-12-08

DUALFLOW

Not yet recruiting

60 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

87 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

Phase 2 Not yet recruiting

90 enrolled

Tumor-Agnostic

Neoplasm, Residual

NCT07045168 2025-09-15

Risk-adapted Therapeutic Strategy in +1q NDMM

Not yet recruiting

200 enrolled

Plasma cell

Multiple Myeloma, Neoplasm, Residual

Clinical Trials

K4CARE-PDAC

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

PREeMPT

RT4

Motixafortide for MRD Sensitization in AML

DEL-MRD-CHID

AlloNK1

CIRCALL

TRACE-BTC

LAL-2025

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical Cancer

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Cancer

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

DUALFLOW

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

MRD-ATLAS

Risk-adapted Therapeutic Strategy in +1q NDMM